HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer

• Published in: American journal of clinical pathology 2024-05, Vol.161 (5), p.436-442
• Main Authors: Xia, Daniel, Kuo, Frank, Hughes, Melissa, Lindeman, Neal, Manning, Danielle, Files, Janet, Strauss, Sarah, Kirkner, Greg, Mohammed-Abreu, Ayesha, Winer, Eric, Tolaney, Sara M, Lin, Nancy U, Dillon, Deborah A
• Format: Article
• Language: English
• Subjects: Biomarkers, Tumor - genetics; Breast Neoplasms - genetics; Breast Neoplasms - pathology; DNA Copy Number Variations; Female; Gene Dosage; High-Throughput Nucleotide Sequencing - methods; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Receptor, ErbB-2 - analysis; Receptor, ErbB-2 - genetics
• ISSN: 0002-9173; 1943-7722
• DOI: 10.1093/ajcp/aqad167

A combination of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) is the current standard of care for HER2 evaluation in breast cancer. Here, we investigate the potential clinical utility of next-generation sequencing (NGS)-derived HER2/ERBB2 copy number (CN) data for predicting HER2 status as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. In total, 294 locally recurrent and metastatic breast cancers previously tested by targeted hybrid capture-based NGS and by HER2 IHC/FISH were included. Analyses focused on the ERBB2 median log2 ratios and start-end genomic coordinates from NGS, average HER2 CN and HER2/CEP17 ratios from FISH, and the HER2 IHC scores. We also determined a more stringent log2 ratio cutoff to predict HER2-positive status with 100% specificity. Sixty-four (22%) cases were HER2 positive and 230 (78%) were HER2 negative by ASCO/CAP guidelines. The ERBB2 median log2 ratios from NGS strongly correlated with HER2 status by IHC/FISH (area under receiver operator characteristic curve = 0.951). ERBB2 log2 ratio more than 1.7 was 100% specific for HER2-positive results by IHC/FISH. Start and end genomic coordinates for regions of gain near ERBB2 by NGS also predicted HER2 status. Copy number data from our NGS panel strongly correlate with HER2 status. Using a stringent cutoff, ERBB2 log2 ratio accurately predicts HER2 positivity with high specificity. The NGS CN assessment may have utility in determining HER2 status in certain clinical settings.